Ginsenoside CK
(Synonyms: 20(S)-人参皂苷 C-K; Compound K) 目录号 : GC20007
Ginsenoside CK，一种由主要人参皂苷化合物转化而来的次级人参皂苷，比其母体人参皂苷具有更高的生物利用度和溶解性，具有极其重要的意义。
Cas No.:39262-14-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ginsenoside CK, a secondary ginsenoside biotransformed from major ginsenosides, is more bioavailable and soluble than its parent ginsenosides and holds great significance[1]. Naturally absent, Ginsenoside CK can be generated from other protopanaxadiol (PPD)-type ginsenosides by the intestinal microflora of humans or rats[2]. As a bacterial metabolite of Ginsenoside-Rb1, Ginsenoside CK exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and proinflammatory cytokines[3]. Ginsenoside CK potently inhibited the production of nitric oxide and prostaglandin E2 in LPS-induced RAW 264.7 cells, with IC50 values of 0.012 and 0.004mM, respectively[4].
In vitro, treatment of HepG2 cells with Ginsenoside CK (8, 4, and 2µM) for 24h resulted in dose-dependent inhibition of hepatic glucose production, accompanied by a decrease in Phosphoenolpyruvate carboxykinase (PEPCK) protein level and an increase in adenosine-5’ monophosphate kinase (AMPK) phosphorylation[5]. Ginsenoside CK (0.01-10µM) was applied to H₂O₂-stimulated MC3T3-E1 cells with or without H₂O₂ for 48h, and the result was found that Ginsenoside CK formed hydrogen bonds with IkBα kinase, increased alkaline phosphatase activity, type I collagen expressions, while decreasing reactive oxygen species and nitric oxide production as well as IL-1β expression[6].
In vivo, DBA/1 mice with collagen-induced arthritis (CIA) were treated with Ginsenoside CK (28, 56, or 112mg/kg/d, ig) or the positive control methotrexate (2mg/kg, ig, every 3d) for 34d, and Ginsenoside CK treatment significantly ameliorated the pathologic manifestations of CIA mice, remarkably inhibited T lymphocyte proliferation, and marginally inhibited the proliferation of B lymphocytes[7]. OLETF rats treated with a high-fat diet (HFD) were administered orally Ginsenoside CK (25 and 10mg/kg) for 12 weeks, which resulted in decreased plasma glucose levels and improved liver cell morphology[8].
References:
[1] Sharma A, Lee HJ. Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities. Biomolecules. 2020;10(7):1028.
[2] Yang XD, Yang YY, Ouyang DS, Yang GP. A review of biotransformation and pharmacology of ginsenoside compound K. Fitoterapia. 2015;100:208-220.
[3] Kim JH, Yi YS, Kim MY, Cho JY. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res. 2017;41(4):435-443.
[4] Park EK, Shin YW, Lee HU, et al. Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biol Pharm Bull. 2005;28(4):652-656.
[5] Wei S, Li W, Yu Y, et al. Ginsenoside Compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: A study in vitro and in vivo. Life Sci. 2015;139:8-15.
[6] Kang S, Siddiqi MH, Yoon SJ, et al. Therapeutic potential of compound K as an IKK inhibitor with implications for osteoarthritis prevention: an in silico and in vitro study. In Vitro Cell Dev Biol Anim. 2016;52(9):895-905.
[7] Liu KK, Wang QT, Yang SM, Chen JY, Wu HX, Wei W. Ginsenoside compound K suppresses the abnormal activation of T lymphocytes in mice with collagen-induced arthritis. Acta Pharmacol Sin. 2014;35(5):599-612.
[8] Hwang YC, Oh DH, Choi MC, et al. Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats. Korean J Intern Med. 2018;33(2):347-355.
Ginsenoside CK，一种由主要人参皂苷化合物转化而来的次级人参皂苷，比其母体人参皂苷具有更高的生物利用度和溶解性，具有极其重要的意义[1]。Ginsenoside CK在自然界中不存在，但可以通过人类或大鼠的肠道微生物群从其他原人参二醇（PPD）型人参皂苷中生成[2]。作为Ginsenoside-Rb1的细菌代谢产物，Ginsenoside CK主要通过减少诱导型一氧化氮合酶（iNOS）、环氧合酶（COX）-2和促炎细胞因子来发挥抗炎作用[3]。Ginsenoside CK在LPS诱导的RAW 264.7细胞中强有力地抑制了一氧化氮和前列腺素E2的产生，其IC₅₀值分别为0.012mM和0.004mM[4]。
在体外，用Ginsenoside CK（8、4和2µM）处理HepG2细胞24小时，结果显示其以剂量依赖性方式抑制肝脏葡萄糖生成，同时伴随着磷酸烯醇式丙酮酸羧激酶（PEPCK）蛋白水平的降低和腺苷-5’-单磷酸激酶（AMPK）磷酸化的增加[5]。将Ginsenoside CK（0.01-10µM）应用于H₂O₂刺激的MC3T3-E1细胞，处理时间为48小时，结果显示Ginsenoside CK与IκBα激酶形成氢键，增加了碱性磷酸酶活性和I型胶原蛋白表达，同时降低了活性氧和一氧化氮的产生以及IL-1β的表达[6]。
在体内实验中，患有胶原诱导性关节炎（CIA）的DBA/1小鼠接受了Ginsenoside CK（28、56或112mg/kg/d，灌胃）或阳性对照药物甲氨蝶呤（2mg/kg，灌胃，每3天一次）治疗，持续34天。结果显示，Ginsenoside CK治疗显著改善了CIA小鼠的病理表现，显著抑制了T淋巴细胞的增殖，并轻度抑制了B淋巴细胞的增殖[7]。采用高脂饮食（HFD）处理的OLETF大鼠口服Ginsenoside CK（25和10mg/kg）12周，结果导致血浆葡萄糖水平降低和肝细胞形态改善[8]。
| Cell experiment [1]: | |
Cell lines | Caco-2 cells |
Preparation Method | Caco-2 cells were routinely grown in DMEM containing 4.5g/L glucose, 0.584g/L glutamine, 10% fetal bovine serum, 3.7% sodium bicarbonate, 100IU/mL penicillin, 100μg/mL streptomycin, and 1% nonessential amino acids. Caco-2 cells were left to differentiate for 15–17 days after confluence. Differentiated human intestinal Caco-2 cells were treated with various concentrations of Ginsenoside CK (1, 0.1, 0.01, and 0.001µM) for 24 to 48h. Subsequently, the protein level and expression of Sodium/glucose cotransporter 1 (SGLT1), as well as the glucose uptake activity of Caco-2 cells, were detected. |
Reaction Conditions | 1, 0.1, 0.01, and 0.001µM; 12, 24, 36, and 48h |
Applications | The results reveal that Ginsenoside CK significantly and gradually induced SGLT1 protein level throughout the study from 24 to 48h (from 1.70- to 2.01-fold, p < 0.05). In addition, Ginsenoside CK also induced SGLT1 expression in a dose-dependent manner over the dose range analyzed, with significant induction at 0.01 and 0.1μM Ginsenoside CK for 1.76- and 2.28-fold, respectively. Ginsenoside CK significantly enhanced glucose uptake activity. |
| Animal experiment [1]: | |
Animal models | C57BL/6 mice |
Preparation Method | C57BL/6 mice that were 6–8 weeks old with a body weight of 16–25g, were randomly divided into control (n = 6) and Ginsenoside CK (n = 6) treatment groups, receiving 1% DMSO and Ginsenoside CK (20mg/kg, dissolved in 1% DMSO) by single oral gavage, respectively. After 30h of Ginsenoside CK administration, the mice were euthanized, and tissue samples were removed for experiments. |
Dosage form | 20mg/kg; 30h; oral gavage |
Applications | Using the SGLT1-specific nonmetabolizable substrate D-[14C]-α-methylglucopyranoside (AMG), the jejunum from mice receiving Ginsenoside CK exhibited increased glucose uptake activity (1.30-fold of control, p < 0.05). In addition, SGLT1 expression level is also significantly increased (1.72-fold of control, p < 0.001) in the jejunum from mice that received Ginsenoside CK. These results indicate that Ginsenoside CK induced SGLT1-mediated glucose uptake and SGLT1 gene expression in vivo. |
References: | |
| Cas No. | 39262-14-1 | SDF | |
| 别名 | 20(S)-人参皂苷 C-K; Compound K | ||
| 分子式 | C36H62O8 | 分子量 | 622.87 |
| 溶解度 | 储存条件 | Store at 2-8°C,protect from light | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6055 mL | 8.0274 mL | 16.0547 mL |
| 5 mM | 0.3211 mL | 1.6055 mL | 3.2109 mL |
| 10 mM | 0.1605 mL | 0.8027 mL | 1.6055 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet